Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Gastroenterology Council for Gut and Liver 2025-05-01
coleção:	Gut and Liver
Assuntos:	infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
Acesso em linha:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!